Royalty Report: Medical, Device, Delivery – Collection: 5301

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Medical
  • Device
  • Delivery
  • Therapeutic
  • Catheter

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 5301

License Grant
The Company entered into a License Agreement with the inventor and his company for the worldwide exclusive rights to exploit certain patents for a needle-free infusion system and connector for the injection of medication into an intravenous attachment.
Field of Use
The rights granted apply to medication.

IPSCIO Record ID: 5780

License Grant
The Licensor hereby grants to Licensee the Exclusive and sublicensable right in the Field in the Territory, under the Patent Rights and Medi-Ject Know How and Improvements only for the Field, to use, have used, sell and have sold, but not manufacture, the Device(s) in the Territory for the Term of this Agreement.
License Property
The Licensor owns valuable Medi-Ject Know How (hereinafter defined) and has been granted patent protection relating to the disposable front-end chamber and adaptor for such needle-free injector devices and Licensor is desirous of developing, Exclusively licensing and supplying such devices in the Territory to Licensee for use in the treatment of human growth disorders and further indications in the Field.  The Licensor has acquired the rights to an improved Device(s) which is a needle-free injector device system capable of delivering drugs through the skin in a controlled manner.

'Disposable Front End Chamber(s)' means a system which is filled with medicant at the time of administration and used to hold and administer the medicant needle-free.

Device(s) means those Medi-Ject needle-free injector devices.

The MJ7 is a needle-free drug delivery system composed of a power pack, a needle-free syringe assembly, an adapter assembly for drawing drug from a traditional glass vial and an adapter cap to serve as a container closure for the drug vial. The power pack is reusable and is connected with the needle-free syringe when injecting or aspirating drug. The device is hand-held and spring powered. The delivered dose can be varied by the user up to the maximum of 0.5 ml in 0.01 ml increments. The needle-free syringe, adapter assembly and adapter cap are the only drug or injection site contacting materials, and these parts and assemblies are provided to the end user as sterile. The device is readied for use, or armed, by manually compressing a spring using a rotating or twisting motion. A similar but opposite twisting motion is used to dose the needle-free syringe when it is attached to the power pack. The drug to be delivered is injected by holding the device against the injection site with slight pressure and in a fashion that the needle-free syringe is in intimate contact with the injection site. Pushing a button which releases the energy stored in the spring triggers the injection. This device includes a safety mechanism that prevents inadvertent firing of the device. The safety is automatically set in the safe or non-firing mode when the device is armed. The safety prevents device actuation by preventing the button from being pushed. The device is primarily cylindrical in shape with a maximum diameter of approximately 1-inch. The length of the device is approximately 6 inches when the spring is fully compressed and the needle-free syringe is not attached. The device is approximately 7 3/4 inches when the device is fully extended at a dosage setting of 0.5 ml and the needle-free syringe is attached. The weight of the device is approximately 1/3 lbs. (135 grams) without the disposable components.

APPENDIX B – PATENTS

U. S. PATENTS – ISSUED

4,507,113               HYPODERMIC JET INJECTOR
Des.304,616           MEDICAMENT INJECTOR
5,062,830               DRY DISPOSABLE NOZZLE ASSEMBLY FOR MEDICAL JET INJECTOR
5,697,917               NOZZLE ASSEMBLY WITH ADJUSTABLE PLUNGER TRAVEL GAP
5,722,953               NOZZLE ASSEMBLY FOR INJECTION DEVICE
5,769,138               NOZZLE AND ADAPTER FOR LOADING MEDICAMENT INTO AN INJECTOR            
5,800,388               PLUNGER/RAM ASSEMBLY ADAPTED FOR A FLUID INJECTOR

5,836,911               INJECTION DEVICE HAVING POSITIONING
5,846,233               COUPLING DEVICE FOR MEDICAL INJECTION SYSTEM
5,865,795               SAFETY MECHANISM FOR INJECTION DEVICES
5,891,085               NOZZLE ASSEMBLY WITH LOST MOTION CONNECTION FOR MEDICAL                                                     INJECTOR ASSEMBLY
5,921,967               PLUNGER FOR NOZZLE ASSEMBLY
5,875,976               LOCKING MECHANISM FOR NOZZLE ASSEMBLY

APPLICATIONS – FILED

60/094,163             LOADING MECHANISM FOR MEDICAL INJECTOR ASSEMBLY
60/094,167             INJECTION-ASSISTING PROBE FOR MEDICAL INJECTOR

Field of Use
Field means using hGH to treat any human ailment.

IPSCIO Record ID: 180208

License Grant
The company entered into an agreement providing the company with exclusive rights in the United States and certain other countries to develop Licensors proprietary intravascular infusion catheter to be used with its SynchroMed® II implantable infusion pump and related infusion system components (together referred to as the Implantable System for Remodulin) in order to deliver Remodulin for the treatment of pulmonary arterial hypertension (PAH).
License Property
The proprietary intravascular infusion catheter is to be used with its SynchroMed® II implantable infusion pump and related infusion system components (together referred to as the Implantable System for Remodulin) in order to deliver Remodulin for the treatment of PAH.  The Implantable System for Remodulin will be exclusive to Remodulin so long as we purchase a minimum percentage of our annual requirement for implantable pump systems from Licensor.
Field of Use
This agreement pertains to the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.